SCHEMBL1165362

SCHEMBL1165362

CC1CN(S(=O)(=O)c2cccc3cnccc23)CCN1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKD3 O94806 5/20 1.00
PRKCG P05129 5/20 1.00
PRKCB P05771 5/20 1.00
PRKCA P17252 5/20 1.00
PRKCH P24723 5/20 1.00
PRKCI P41743 5/20 1.00
PRKCE Q02156 5/20 1.00
PRKCQ Q04759 5/20 1.00
PRKCZ Q05513 5/20 1.00
PRKCD Q05655 5/20 1.00
PRKD1 Q15139 5/20 1.00
CYP3A4 P08684 4/20 1.00
CYP2D6 P10635 3/20 1.00
NFKB1 P19838 2/20 1.00
PRKACA P17612 4/20 0.70
PRKACG P22612 4/20 0.70
PRKACB P22694 4/20 0.70
ADORA3 P0DMS8 2/20 0.70
CYP2C19 P33261 2/20 0.70
KDM4E B2RXH2 1/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30084457 1.00 PRKD3 (1.00) PRKD3PRKCGPRKCBPRKCAPRKCH
Hydrochloric Acid SCHEMBL20553518 0.99 PRKD3 (0.98) PRKD3PRKCGPRKCBPRKCAPRKCH
Hydrochloric Acid SCHEMBL1321843 0.99 PRKD3 (0.98) PRKD3PRKCGPRKCBPRKCAPRKCH
SCHEMBL2457955 0.93 PRKD3 (0.87) PRKD3PRKCGPRKCBPRKCAPRKCH
SCHEMBL18599911 0.93 PRKD3 (0.87) PRKD3PRKCGPRKCBPRKCAPRKCH
SCHEMBL23951537 0.89 PRKD3 (0.81) PRKD3PRKCGPRKCBPRKCAPRKCH
SCHEMBL9016187 0.87 PRKD3 (0.77) PRKD3PRKCGPRKCBPRKCAPRKCH
SCHEMBL10982199 0.87 PRKD3 (0.77) PRKD3PRKCGPRKCBPRKCAPRKCH
SCHEMBL10988093 0.87 PRKD3 (0.77) PRKD3PRKCGPRKCBPRKCAPRKCH
SCHEMBL2456661 0.85 PRKD3 (0.74) PRKD3PRKCGPRKCBPRKCAPRKCH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10913932-B2 Maturation of mammalian hepatocytes TAKARA BIO EUROPE AB (SE) 2021-02-09 US claimed
US-9006394-B2 Peptide-presenting surfaces for long-term culture of pluripotent cells WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2015-04-14 US claimed
US-20140287505-A1 PEPTIDE-PRESENTING SURFACES FOR LONG-TERM CULTURE OF PLURIPOTENT CELLS WISCONSIN ALUMNI RESEARCH FOUNDATION 2014-09-25 US claimed
US-8648170-B2 Peptide-presenting surfaces for long-term culture of pluripotent cells WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2014-02-11 US claimed
EP-1479386-A1 Use of isoquinoline-derivatives for treating and preventing pigmentary disorders Switch Biotech Aktiengesellschaft (DE) 2004-11-24 EP claimed
US-12529032-B2 Methods and culture substrates for controlled induction of biomimetic neural tissues comprising singular rosette structures WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2026-01-20 US disclosed
US-20250346858-A1 METHODS OF GENERATING THREE-DIMENSIONAL RETINAL ORGANOIDS FROM HUMAN PLURIPOTENT STEM CELLS UNIV INDIANA TRUSTEES (US) 2025-11-13 US disclosed
US-20250207101-A1 NEXT GENERATION DESIGNER LIVER ORGANOIDS AND THEIR METHODS OF PREPARATION AND USE UNIV ARIZONA STATE (US) 2025-06-26 US disclosed
WO-2025094630-A1 METHOD FOR PRODUCING THREE-DIMENSIONAL SKIN TISSUE, AND THREE-DIMENSIONAL SKIN TISSUE ポーラ化成工業株式会社 2025-05-08 WO disclosed
US-12275957-B2 Next generation designer liver organoids and their methods of preparation and use ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2025-04-15 US disclosed
US-20250034523-A1 METHODS OF GENERATING HUMAN COCHLEAR HAIR CELLS THE TRUSTEES OF INDIANA UNIVERSITY 2025-01-30 US disclosed
US-20240335593-A1 GENERATING ALLOGENIC ENDOTHELIAL CELL-SEEDED VASCULAR GRAFTS AND METHODS OF USE THEREOF WISCONSIN ALUMNI RESEARCH FOUNDATION 2024-10-10 US disclosed
CN-1233188-A Medicines comprising Rho kinase inhibitor YOSHITOMI PHARMACEUTICAL (JP) 1999-10-27 CN disclosed
US-5747507-A MYOCARDIAL DISEASE ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) 1998-05-05 US disclosed
EP-0654266-A1 CARDIAC PROTECTIVE Asahi Kasei Kogyo Kabushiki Kaisha (JP) 1995-05-24 EP disclosed
US-4560755-A VASODILATOR, HYPOTENSOR ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) 1985-12-24 US disclosed
US-4525589-A Isoquinolinesulfonyl derivatives ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) 1985-06-25 US disclosed
EP-0061673-B1 ISOQUINOLINESULFONYL DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF Asahi Kasei Kogyo Kabushiki Kaisha (JP) 1984-10-24 EP disclosed
US-4456757-A MUSCLE RELAXANTS, VASODILATORS, HYPOTENSIVE AGENTS ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) 1984-06-26 US disclosed
EP-0061673-A1 Isoquinolinesulfonyl derivatives and process for the preparation thereof Asahi Kasei Kogyo Kabushiki Kaisha (JP) 1982-10-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12529032-B2 Methods and culture substrates for controlled induction of biomimetic neural tissues comprising singular rosette structures NES, CDH1, SHH PRKD3 774/4885PRKCG 430/4885PRKCB 316/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.